The Antiviral Effect of Switching From Hard Capsule Saquinavir SQVhc to the Soft Gelatin Capsule of Saquinavir SQVsc Versus Switching to Indinavir IDV After 1 Year of Saquinavir Use
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2021-11-04
144
Participants Needed
16
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
To determine, in HIV-infected patients, whether switching to a new soft gelatin capsule formulation of saquinavir or to indinavir following prolonged use of the original hard capsule formulation of saquinavir results in an acute decrease in plasma HIV RNA.
Resistance to anti-HIV agents occurs with increasing duration of use. In vitro studies have shown that cross-resistance occurs among protease inhibitors, although no clinical trials have been conducted to examine antiretroviral activity with sequential use of protease inhibitors or to determine whether saquinavir resistance can be overcome with higher concentrations of the drug.
CONDITIONS
Brief Title
The Anti-HIV Effects of Saquinavir Soft Gelatin Capsules Versus Indinavir in Patients Who Have Used Saquinavir Hard Gelatin Capsules for One Year
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
Inclusion Criteria
Concurrent Medication:
Required:
PCP prophylaxis if CD4 count <= 200 cells/mm3.
Allowed:
Intralesional therapy for KS.
Vitamins.
Nucleoside RT inhibitors, provided regimen remains stable for first 8 weeks of study.
Concurrent Treatment:
Allowed:
Acupuncture.
Visualization techniques.
Patients must have:
HIV infection.
Prior hard capsule saquinavir at 1800 mg/day for more than 1 year.
Prior Medication:
Allowed:
Prior saquinavir.
Prior antiretrovirals, excluding protease inhibitors other than saquinavir.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Psychological condition or medical instability that would interfere with study evaluation or procedures.
AS PER AMENDMENT 5/7/97:
Active tuberculosis.
Concurrent Medication:
Excluded:
Protease inhibitors other than study drugs.
Non-nucleoside RT inhibitors.
Interferon.
Interleukins.
GM-CSF.
HIV vaccines.
Systemic cytotoxic chemotherapy.
Investigational drugs other than study medications.
Rifabutin.
Rifampin.
Midazolam.
Triazolam.
Ketoconazole.
Delavirdine.
Cisapride.
Terfenadine.
Astemizole.
AS PER AMENDMENT 5/7/97:
Nevirapine.
Patients with the following prior conditions are excluded:
Unexplained fever > 38.5 C for any 7 days within 30 days prior to study entry.
Diarrhea persisting for 15 days within 30 days prior to study entry.
Prior Medication:
Excluded:
Any prior protease inhibitor other than saquinavir.
Excluded within the past 2 months.
Change in antiretroviral regimen.
Systemic chemotherapy for KS.
Excluded within the past month:
Non-nucleoside RT inhibitors.
Interferons.
Interleukins.
HIV vaccines.
Experimental therapies.
Excluded within the past 2 weeks:
Rifabutin.
Cisapride.
Terfenadine.
Astemizole.
Midazolam.
Triazolam.
Oral ketoconazole.
Delavirdine.
Acute therapy for infection or other medical illness.
Active substance abuse that would interfere with study evaluation or procedures.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
TREATMENT
Number of Arms
0
Similar Trials
Continued Access Study Providing Ongoing HIV Treatment for Participants from ViiV Healthcare Parent Studies
Long-Term Follow-Up Study of HIV-Infected Individuals from HIV-NAT Trials to Evaluate Clinical Outcomes and Treatment Effects
Phase 2b Study Comparing Oral VH4524184 with Standard HIV Treatment in Adults Newly Diagnosed with HIV-1
Evaluating Treatment Strategies for Managing Virologic Failure on Tenofovir, Lamivudine, and Dolutegravir TLD in People with HIV in Sub-Saharan Africa
Pilot Study of a Peer-Driven Injection Setting Intervention to Prevent HIV, Hepatitis C, and Overdose Among People Who Inject Drugs in Baltimore
Phase 1 Study of VH4011499 Safety, Tolerability, and Pharmacokinetics
with Single and Multiple Doses in Adults Without HIV
Safety and Effectiveness of JL18008 Injections Added to Standard HIV Therapy
in Adults with HIV Who Have Low Immune Response
A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Phase 12 Study to Assess Safety and Effects of Cabotegravir in Newborns Exposed to HIV-1
Phase III Study Comparing Cabotegravir and Rilpivirine Ultra Long-Acting or Long-Acting Treatments in Adolescents and Adults With Suppressed HIV
Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of Single-Dose VH4367310 in Healthy Adults Aged 18 to 55 Years
Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS clinical trials group 333.
Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333.